 MALVERN, Pa., Oct. 05, 2021 GLOBE NEWSWIRE -- Neuronetics, Inc. NASDAQ: STIM, a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced a commercial agreement with Success TMS in which Success TMS will exclusively utilize Neuronetics platform, NeuroStar Advanced Therapy for Mental Health, for the treatment of patients suffering from treatment-resistant major depressive disorder MDD. In connection with the commercial agreement, the Company has made a strategic investment in Success TMS in the form of a 10 million term loan to further accelerate the growth of Success TMS business. 